Drug intelligence / Profile preview

[18F]BBPA

Development stage
Unknown
Lead developer
BoomRay Pharmaceuticals
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

[18F]BBPA (also known as BR-02 or [18F]BF3-BPA) is an investigational, unapproved small-molecule radiopharmaceutical and PET tracer. It is a trifluoroborate-derived boronophenylalanine (a bis-boron boramino acid) designed for the positron emission tomography (PET) imaging of primary and metastatic brain tumors, such as gliomas. It acts as a pan-cancer probe, entering cells via the large neutral amino acid transporter type-1 (LAT-1). Because it shares an identical chemical structure with boron carriers used in boron neutron capture therapy (BNCT) (with the only difference being the fluorine isotope), [18F]BBPA serves as a theranostic agent to estimate tumor boron concentration prior to BNCT. It exhibits rapid clearance, low normal-tissue affinity, and a short elimination half-life.

Other names
18F-BBPA18F-BF3-BPA[18F]BF3-BPAbis-boron boramino acidbis-boron boronophenylalaninetrifluoroborate boronophenylalaninetrifluoroborate-derived boronophenylalanine
02

Targets

SLC7A5 (Large neutral amino acid transporter small subunit 1)

Beyond the preview

Go deeper on [18F]BBPA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]BBPA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call